Loren Data's SAM Daily™

FBO DAILY ISSUE OF DECEMBER 08, 2005 FBO #1473
MODIFICATION

A -- E Coli Oligonucleotide Library

Notice Date

11/3/2005
 

Notice Type

Modification
 

NAICS

541710 — Research and Development in the Physical, Engineering, and Life Sciences
 

Contracting Office

Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, MD, 20857-0001
 

ZIP Code

20857-0001
 

Solicitation Number

1010733
 

Response Due

11/7/2005
 

Point of Contact

Alice Pagán, Contract Specialist, Phone (301) 827-7104, Fax (301) 827-7101,
 

E-Mail Address

APagan@oc.fda.gov
 

Description

This Amendment will include the following answers to questions submitted by a potential offeror: 1) What is the duration of purchase order/within what time period this 10000 oligonucleotides must be delivered? We will need all 10,000 oligonucleotides shipped within 30 days of receiving the purchase order. 2) Any purification is needed for these oligonucleotides? Purification should include deprotection and desalting in order to remove small molecule impurities. The Food and Drug Administration intends to award a Purchase Order for an E Coli Oligonucleotide Library on a competitive basis. The requested oligonucleotide library must satisfy each of the following requirements: 1.Include 10,000 custom 70-mer oligonucleotides. 2.Each oligonucleotide must be nomalized to a final concentration of 100 micromolar. 3.100 microliters of each normalized oligonucleotide should be shipped in 384-well plates. (these criteria require a minimum yield of 10 nanomoles for each oligonucleotide). 4.Any additional oligonucleotide synthesized (in excess of 10 nanomoles) should also be normalized to a concentration of 100 micromolar and also shipped in a separate set of 384-well plates. 5.EACH oligonucleotide synthesized must undergo a quality control assay such as capillary electrophoresis or mass spectrometry in order to verify its purity and integrity and the results of these assays must be provided when the oligonucleotides are shipped. This announcement constitutes the only solicitation. NO REQUEST FOR QUOTE (RFQ) IS AVAILABLE. Interested offerors shall submit their capabilities statement along with their cost quotation, which will be considered if received by the tenth (10th) calendar day following the appearance of this announcement. Award will be made to the vendor who submits the lowest price that meets all specifications and requirements. All responses or questions regarding this posting must be in writing and can be sent via email to Apagan@oc.fda.gov. No phone calls will be accepted. An award will be made in ten (10) calendar days from the date of this notice. This procurement will be awarded as a simplified acquisition for commercial items in accordance with FAR Subpart 13.5. NOTE: THIS NOTICE MAY HAVE POSTED ON FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (03-NOV-2005). IT ACTUALLY APPEARED OR REAPPEARED ON THE FEDBIZOPPS SYSTEM ON 06-DEC-2005, BUT REAPPEARED IN THE FTP FEED FOR THIS POSTING DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
 

Web Link

Link to FedBizOpps document.
(http://www.fbo.gov/spg/HHS/FDA/DCASC/1010733/listing.html)
 

Place of Performance

Address: FDA/CFSAN 8301 MUIRKIRK ROAD LAUREL, MARYLAND

Zip Code: 20708

Country: USA
 

Record

SN00947106-F 20051208/051207100010 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |